Tekcapital Reports Record Net Assets and Guident IPO Momentum in H1 2025

Tekcapital’s H1 2025: record net assets, tighter costs, and a clear shot at a Guident IPO

Tekcapital has posted another profitable half and set a new high-water mark for net assets. The group’s investing strategy – founding and scaling university spinouts in GenAI, smart eyewear, autonomous systems and better-for-you food – continues to do the heavy lifting, with portfolio gains offsetting a step down in reported revenue. Costs have been trimmed hard, and the spotlight now swings to Guident’s potential NASDAQ listing.

Headline numbers at a glance

Two important definitions for newer investors: NAV per share is the value of net assets divided by the share count; it held steady at US$0.33 despite growth in absolute net assets, reflecting new equity issuance. “Fair value gains” are revaluations of the portfolio holdings that flow through the income statement.

Where the profit came from

The income mix is the real story. Of the US$6.17m total portfolio return and revenue, services revenue was US$139,140 and interest US$336,858, with the bulk made up by changes in fair value of financial assets at US$5.70m. That tells you performance was mainly driven by portfolio appreciation rather than cash trading income – typical for an IP investment group, but it does mean reported earnings will remain lumpy period to period.

On the cost side, the company has clearly tightened the belt. Operating expenses fell 50% to US$0.7m versus H1 2024, which is impressive and directly supportive of future shareholder returns if gains continue.

Guident IPO momentum – the potential catalyst

Guident, Tekcapital’s autonomous vehicle safety and robotics platform, is stepping into the limelight. The company submitted a draft registration statement earlier in the period and, post period end, publicly filed its S-1 as it targets a NASDAQ IPO. Tekcapital owns ~70% of Guident Corp on a fully diluted basis, with that stake valued at US$22.9m as at 30 June 2025.

Why this matters:

• Crystallisation of value: a successful listing could put a public price on Tekcapital’s largest unlisted asset and reduce the valuation discount typically applied to private holdings.
• Liquidity and returns: management explicitly flags that a Guident IPO “has the potential to crystallise significant balance sheet value and facilitate future issuances of special dividends.” That is not guidance, but it sets expectations for how exits may be shared.
• Execution risk: listings depend on market conditions and issuer readiness. There is no timetable disclosed, so investors should watch for pricing, valuation and any cornerstone interest when the deal launches.

Operationally, Guident announced contracts for its WatchBot autonomous inspection robots, a remote teleoperation milestone with a Level 4 electric bus at Michigan State University, ISO/IEC 27001:2022 certification, and a planned shuttle service in Boca Raton starting October 2025. This is the sort of commercial traction that supports an IPO narrative.

Microsalt: scale-up continues with QSR focus

Microsalt posted strong commercial momentum: record bulk sales in Q1 2025, market expansion into Great Britain and Belgium, and the launch of MicroSalt Premium targeting quick service and fast service restaurants (QSR/FSR), with French fries a focus. A top international brand is considering a 2026 rollout, per Microsalt’s H1 update.

• FY 2025 sales target: US$2.0m.
• Volume projections from a major customer indicate potential sales exceeding US$5m in 2026 and expanding to US$11m in 2027 for one major application.
• Oversubscribed fundraising of £2.3 million completed.

Tekcapital owns 62.94% of Microsalt, valued at US$39.5m at 30 June 2025. In my view, Microsalt’s near-term revenue target is modest, but the multi-year pipeline and QSR interest are the punchline. Execution on the 2026-2027 opportunity matters more than the 2025 print.

GenIP: early GenAI revenues with blue-chip validation

GenIP secured a US$0.35m contract in Saudi Arabia covering 400 GenAI analytical assessments, launched a Competitive Intelligence Report, and signed its first client for that product – a Big Four accountancy firm. Since launching its GenAI services in September 2024, GenIP has booked over US$981k of Invention Evaluator orders.

Ownership and value: Tekcapital held 63.08% of GenIP, valued at US$5.7m at period end. Post period, GenIP reported cash of US$1,077k at 30 June 2025 and US$488k of new orders in H1 2025, plus a strategic role with a Chilean GreenTech platform serving 400+ members. It is still early, but the order book and cash discipline point in the right direction.

Innovative Eyewear (Lucyd): retail partnerships and feature upgrades

Innovative Eyewear launched Reebok Smart Eyewear, broadened distribution via a 600+ store optometry network in Canada, and added a multi-language translation feature to the Lucyd app. Sales for the six months to 30 June 2025 rose 49% with flat G&A and sales and marketing expenses. Post period, Q2 net revenue was US$579,230, up 88% year-on-year, with year-to-date revenue at US$1,033,731, up 49%.

Tekcapital owns approximately 5.7%, valued at US$0.6m at 30 June 2025. The mix of brand partnership, retail access and product utility is improving; the key question is sustained sell-through into 2026.

Belluscura: small stake, big uncertainty

Demand for the X-PLOR portable oxygen concentrator remains, but Belluscura faces working capital constraints. Post period, the company announced director resignations, a 15-employee reduction in its U.S. staff, and a temporary suspension of trading on AIM pending annual accounts, while seeking additional funding.

Tekcapital’s exposure here is small: 2.1% valued at US$0.1m as of 30 June 2025. The commentary is frank – success hinges on financing.

Balance sheet, cash and dilution watch

Tekcapital ended the half with cash of US$1.31m and total liabilities of US$497,600. There is no third-party debt. Operating cash outflow was US$932,168, partly reflecting the group’s low-cost base but also the nature of investment operations. Share placements raised US$2.3m in H1, with net cash increasing by US$515,584 over the period.

NAV per share held at US$0.33 despite net assets rising to US$77.4m, indicating that equity issuance broadly balanced the uplift. That is acceptable so long as new capital is deployed into value-accretive milestones like Guident’s IPO readiness and Microsalt scaling.

Portfolio valuation movements

Within the fair value line:

• Guident Limited increased to US$22.9m, including new funding activity reflected in the convertible loan movements.
• Microsalt plc rose to US$39.5m, aided by foreign exchange and fair value uplift.
• GenIP increased to US$5.68m with positive fair value change.
• Belluscura fell to US$86,122.
• Lucyd Limited was valued at US$550,045.

This mix underscores the concentration of value in Microsalt and Guident – helpful when they execute, but a reminder that NAV will remain sensitive to those two names.

The good, the bad, and what to watch

Positives

• Record net assets of US$77.4m and another profitable half-year (US$5.43m profit after tax).
• Operating expenses cut by 50% to US$0.7m – a leaner platform.
• Clear external milestones: Guident’s S-1 filed, Microsalt QSR pipeline, GenIP contract wins, and Lucyd’s revenue growth.

Negative or cautionary points

• Revenue fell versus the unusually strong H1 2024 and remains dominated by fair value gains, so earnings will be volatile.
• Cash balance is modest at US$1.31m; placements remain part of the playbook until exits fund the machine.
• Belluscura’s financing uncertainty persists, although Tekcapital’s stake is small.

Key catalysts for the second half

• Guident IPO: deal launch details, valuation and timing. This is the near-term swing factor for NAV and potential special dividends, as flagged by the Chairman.
• Microsalt: progress on QSR/FSR adoption and confirmation of 2026 volume commitments.
• GenIP: conversion of its order pipeline and further blue-chip wins.
• Innovative Eyewear: sustained sell-through of Reebok Smart Eyewear and traction for Lucyd Armor.
• Belluscura: funding outcome and resumption of trading.

Josh’s take

This is a tidy set of numbers with a clear narrative: leaner overheads, growing portfolio value, and an IPO catalyst in sight. NAV per share was held flat, which is fine given the raise, and the portfolio composition looks increasingly commercial rather than purely developmental. The flip side is that reported profits hinge on fair value movements, so expect continued lumpiness. If Guident lists well and Microsalt lands its QSR opportunity, Tekcapital’s strategy of building and floating its own portfolio companies will have another strong validation point. Until then, it is about execution, liquidity management and delivering those milestones.